Videos |View More
This CME-accredited activity, the Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting, is a two-day symposium designed to provide an engaging and interactive forum for discussing the ...
Meet the Team: Dr. Ehsan Malek
As the Director of the Multiple Myeloma Translational Research Program at Roswell Park, Dr. Malek brings with him a passion for finding new and innovative treatments for this disease and other plasma cell disorders
Diagnosis and Co-management of Hematologic Malignancies for the Primary Care Provider
Our expert speakers dive into the latest techniques in diagnostics, treatment modalities, and interdisciplinary approaches, providing attendees with valuable insights to enhance patient care and outcomes.
Updates and Advancements in Cellular Therapy at Roswell Park
Originally Broadcast: Thursday, November 9, 2023 6:00 - 7:30 PM EST - This program is intended for Hematologists, Oncologists, Pharmacists, Pathologists, and other healthcare professionals that care for cancer patients.
The New York State Cellular Therapy Consortium
This is a clinically oriented educational program intended for hematologists, oncologists, pharmacists, pathologists, and other healthcare professionals that may diagnose, treat, or manage patients with cancer. The goal is to educate participants ...
Roswell Park Welcomes New Vice Chair of Clinical Affairs: Dr. Peter Maslak
Peter Maslak, MD, is an expert Hematologic Oncologist, joining Roswell Park as Vice Chair of Clinical Affairs, Director of Flow Cytometry in the Immune Monitoring Shared Resource and the Technical Director of the Flow Cytometry Lab.
Roswell Park Welcomes New Chief of Lymphoma Clinical Section: Dorothy Pan, MD
Dorothy Pan, MD, is joining Roswell Park Comprehensive Cancer Center as the Chief of the Lymphoma Clinical Section in the Department of Medicine.
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan ...
Physician-Scientist Marco Davila, MD, PhD, Joins Growing Roswell Park Cellular Therapy Program
Following a national search, Roswell Park Comprehensive Cancer Center has appointed Marco Davila, MD, PhD, as Senior Vice President and Associate Director for Translational Research and Vice-Chair for Cellular Therapies.
News |View More
A single infusion of the CAR T cell therapy ciltacabtagene autoleucel produced deep, durable responses in multiple myeloma patients whose disease had progressed less than a year after autologous stem cell transplant (ASCT) or who experienced ...
Replacing brentuximab vedotin with nivolumab in first-line treatment combined with the chemotherapy regimen AVD improved progression-free survival in pediatric patients with newly diagnosed, advanced-stage classic Hodgkin lymphoma (cHL), ...
Clinical Trial Evaluates Triple-Drug Regimen for Patients Newly Diagnosed with FLT3-Mutated AML
Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis. To complicate matters, often they are ineligible for intensive ...
Because most multiple myeloma patients are 65 or older, including some who are frail, successive lines of therapy to address relapsed disease often take their toll — so keeping patients in deep remission after frontline treatment is highly desirable.
Investigators at Roswell Park Comprehensive Cancer Center hope a new clinical trial will pave the way for a new time-limited, oral-delivery treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) ...
As work advances on a significant expansion of its cellular therapy production and research facilities, Roswell Park Comprehensive Cancer Center has named Yeong “Christopher” Choi, PhD, MBA, as Senior Vice President of Industry Partnerships ...
A clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a nonpharmaceutical method ...
BUFFALO, N.Y. — Eunice S. Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, led a research effort that supports the addition of gemtuzumab ozogamicin—a CD33-directed antibody-drug conjugate—to standard induction ...
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
BUFFALO, N.Y. and ATLANTA, GA. — A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children’s Oncology ...
This site is intended for healthcare professionals